OTC: PBIGF - Paradigm Biopharmaceuticals Limited

Yield per half year: +121.59%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Paradigm Biopharmaceuticals Limited

Extended chart Simple chart
Financial Markets by TradingView

About Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.paradigmbiopharma.com
Цена ао 0.3807
Change price per day: 0% (0.3807)
Change price per week: 0% (0.3807)
Change price per month: +8.77% (0.35)
Change price per 3 month: +170.96% (0.1405)
Change price per half year: +121.59% (0.1718)
Change price per year: +63.25% (0.2332)
Change price per 3 year: -60.55% (0.9649)
Change price per 5 year: -87.31% (3)
Change price per 10 year: 0% (0.3807)
Change price per year to date: +170.96% (0.1405)
All parameters

Underestimation

Title Value Grade
P/S 1207.21 1
P/BV 3.34 5
P/E 0 0
EV/EBITDA -1.06 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -91.65 0
ROE, % -112.45 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0041 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -97.79 0
Yield Ebitda, % 385.35 10
Yield EPS, % 209.58 10
Total: 8
More

Institutions Volume Share, %
Vanguard International Stock Index-Total Intl Stock Indx 3456896 0.99
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 2117667 0.6
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 1055062 0.3
Vanguard International Stock Index-Pacific Stock Index 392059 0.11
SPDR Portfolio Developed World ex-US ETF 169911 0.05
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF 105574 0.03
Vanguard Intl Equity Index - Total World Stock Index Fd 71921 0.02
DFA Asia Pacific Small Company Series 59638 0.02
Vanguard World Fund-Vanguard ESG International Stock ETF 43440 0.01



Head Job title Payment Year of birth
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Founder, MD & Executive Chairman 1.17M 1959 (66 years)
Dr. Donna L. Skerrett M.D., MS Chief Medical Officer and Executive Director 843.69k 1957 (68 years)
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. Company Secretary & CFO N/A
Dr. Ravi Krishnan Chief Scientific Officer N/A
Mr. Simon White Director of Investor Relations N/A
Dr. Michael Imperiale Global Head of Drug Safety & MPS N/A
Ms. Beverley Huttmann Commercial Head N/A
Ms. Michelle Coffey Global Head of Regulatory Affairs N/A
Dr. Mukesh Ahuja Global Clinical Head of OA N/A

Address: Australia, Melbourne, 500 Collins Street - open in Google maps, open in Yandex maps
Website: https://www.paradigmbiopharma.com